InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
-0.04%
)
US TECH 100
19,168.00
(
0.52%
)
Dow Jones
38,589.16
(
-0.15%
)
Brent Oil
82.28
(
0.00%
)
Bitcoin
66,108.95
(
0.16%
)
Post# of 252190
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119841
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 164743

Thursday, 01/09/2014 2:16:32 PM

Thursday, January 09, 2014 2:16:32 PM

Post# of 252190
Re: Interim phase-2 data on VX-135 + Daclatasvir

VRTX reports SVR4 rate of 83% (10/12) in high-dose cohort of open-label phase-2 study of VX-135 + BMY’s Daclatasvir in treatment-naïve GT1 patients:

http://finance.yahoo.com/news/vertex-announces-sustained-viral-response-133000898.html

Of the 12 patients in the 200mg* cohort of VX-135, one patient dropped out because of an SAE and one patient completed treatment but relapsed or didn’t respond to treatment.

The data from the 100mg cohort of VX-135 are worse (see press release). I stand by the assertion in #msg-90498491.

*FDA has a clinical hold on the 200mg dose of VX-135.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up